Investigational New Drugs

, Volume 27, Issue 2, pp 99–110 | Cite as

Sulfinosine enhances doxorubicin efficacy through synergism and by reversing multidrug resistance in the human non-small cell lung carcinoma cell line (NCI-H460/R)

  • Milica Pešić
  • Tijana Andjelković
  • Jasna Banković
  • Ivanka D. Marković
  • Ljubiša Rakić
  • Sabera RuždijićEmail author


A resistant non-small cell lung carcinoma cell line—NSCLC (NCI-H460/R) was established in order to investigate the potential of sulfinosine (SF) to overcome multidrug resistance (MDR). The cytotoxicity of doxorubicin (DOX) in NCI-H460/R cells was enhanced by interaction with SF. SF improved the sensitivity of resistant cells to DOX when NCI-H460/R cells were pretreated with SF. Synergism was accompanied by the accumulation of cells in S and G2/M phases. Pretreatment with SF was more potent in improving the sensitivity to DOX than verapamil (VER). The decrease of mdr1 and topo II α expression (assessed by RT-PCR), was consistent with the DOX accumulation assay and cell cycle analysis. Also, SF significantly decreased intracellular glutathione (GSH) concentration. These results point to SF as a potential agent of MDR reversal and a valuable drug for improving chemotherapy of NSCLC.


NSCLC Multidrug Resistance, Sulfinosine Doxorubicin Drug Combination, Glutathione 



This study was supported by grant #143009B from the Ministry of Science, Republic of Serbia.


  1. 1.
    Yang P, Ebbert JO, Sun Z, Weinshilboum RM (2006) Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol 24:1761–1769PubMedCrossRefGoogle Scholar
  2. 2.
    Kanters SD, Lammers JW, Voest EE (1995) Molecular and biological factors in the prognosis of non-small cell lung cancer. Eur Respir J 8:1389–1397PubMedCrossRefGoogle Scholar
  3. 3.
    Perez-Tomas R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–1876PubMedCrossRefGoogle Scholar
  4. 4.
    Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer role of ATP-dependent transporters. Nat Rev Cancer 2:48–58PubMedCrossRefGoogle Scholar
  5. 5.
    Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253–265PubMedCrossRefGoogle Scholar
  6. 6.
    Ozols RF, Cunnion RE, Klecker RW Jr, Hamilton TC, Ostchega Y, Parrillo JE, Young RC (1987) Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641–647PubMedGoogle Scholar
  7. 7.
    Fisher GA, Lum BL, Sikic BI (1995) The reversal of multidrug resistance. Cancer Treat Res 78:45–70PubMedGoogle Scholar
  8. 8.
    Lum BL, Gosland MP (1995) MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol Oncol Clin North Am 9:319–336PubMedGoogle Scholar
  9. 9.
    Nobili S, Landini I, Gigolini B, Mini E (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861–879PubMedCrossRefGoogle Scholar
  10. 10.
    Bertram J, Palfner K, Killian M, Brysch W, Schlingensiepen KH, Hiddemann W, Kneba M (1995) Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs 6:124–134PubMedCrossRefGoogle Scholar
  11. 11.
    Duan Z, Brakora KA, Seiden MV (2004) Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 3:833–838PubMedGoogle Scholar
  12. 12.
    Wu H, Hait WN, Yang JM (2003) Small interfering RNA-induced suppression of MDR1 (Pglycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63:1515–1519PubMedGoogle Scholar
  13. 13.
    Pesic M, Markovic JZ, Jankovic D, Kanazir S, Markovic ID, Rakic L, Ruzdijic S (2006) Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 18:66–73PubMedGoogle Scholar
  14. 14.
    Melvin JB, Haight TH, Leduc EH (1984) Cytological effects of sulfur and selenium purine analogues on two transplantable hepatomas and on normal renewing cells in mice. Cancer Res 44:2794–2798PubMedGoogle Scholar
  15. 15.
    Revankar GR, Hanna NB, Immamura N, Lewis AF, Larson SB, Finch RA et al (1990) Synthesis and in vivo antitumor activity of 2-amino-9H -purine-6-sulfenamide,- sulfinamide, and -sulfonamide and related purine ribonucleosides. J Med Chem 33:121–129PubMedCrossRefGoogle Scholar
  16. 16.
    Avery TL, Finch RA, Vasquez KM, Radparvar S, Hanna NB, Revankar GR, Robins RK (1990) Chemotherapeutic characterization in mice of 2-amino-9-beta-Dribofuranosylpurine-6-sulfinamide (sulfinosine), a novel purine nucleoside with unique antitumor properties. Cancer Res 50:2625–2630PubMedGoogle Scholar
  17. 17.
    Pogrebniak A, Hasmann M, Schemainda I, Pelka-Fleischer R, Nuessler V (2002) Cytoprotective features of selenazofurin in hematopoietic cells. Int J Clin Pharmacol Ther 40:368–375PubMedGoogle Scholar
  18. 18.
    Milosevic J, Kanazir S, Medic-Mijacevic L, Pejanovic V, Stokic Z, Konjevic G, Ruzdijic S (2002) Sulfinosine-induced cell growth inhibition and apoptosis in human lung carcinomas in vitro. Invest New Drugs 20:229–240PubMedCrossRefGoogle Scholar
  19. 19.
    Jankovic D, Pesic M, Markovic J, Kanazir S, Markovic I, Rakic L, Ruzdijic S (2006) The combination of sulfinosine and 8-Cl-cAMP induces synergistic cell growth inhibition of the human neuroblastoma cell line in vitro. Invest New Drugs 24:15–25PubMedCrossRefGoogle Scholar
  20. 20.
    Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 292:470–484PubMedCrossRefGoogle Scholar
  21. 21.
    Matsumura S, Hoshino T, Weizsaecker M, Deen DF (1983) Paradoxical behavior of 6-mercaptopurine as a cytotoxic agent: decreasing cell kill with increasing drug dose. Cancer Treat Rep 67:475–480PubMedGoogle Scholar
  22. 22.
    Willis RC, Fujitaki JM, Matsumoto SS (1989) In vitro antitumor activity of sulfinosine, 2-amino-9-(β-D-ribofuranosyl) purine-6-sulfinamide and other related nucleosides. Proc Am Assoc Cancer Res 30:597Google Scholar
  23. 23.
    Fujitaki JM, Nord LD, Willis RC (1989) Cellular metabolism of the antitumor nucleoside, sulfinosine, 2-amino-9-(β-D-ribofuranosyl)purine-6-sulfinamide. Proc Am Assoc Cancer Res 30:596Google Scholar
  24. 24.
    Bosch TM, Meijerman I, Beijnen JH, Schellens JH (2006) Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 45:253–285PubMedCrossRefGoogle Scholar
  25. 25.
    Riley TA, Finch RA, Vasquez KM (1989) Isolation, identification, synthesis and therapeutic evaluation of selected metabolites of sulfinosine, a novel purine nucleoside analog active against thiopurine refractory experimental leukemia. Proc Am Assoc Cancer Res 30:599Google Scholar
  26. 26.
    Crabtree GW, Finch RA, Vasquez KM (1989) Cysteine and glutathione competition for adduct formation with 2-amino-9-(β-D-ribofuranosyl)purine-6-sulfinamide (sulfinosine, fin) modulates therapeutic efficacy. Proc Am Assoc Cancer Res 30:597Google Scholar
  27. 27.
    Chou J, Chou TC (1987) (eds) Dose-effect analysis with microcomputers: Quantification of ED50, LD50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics. In Manual and software for IBM-PC. Biosoft, Cambrige, EnglandGoogle Scholar
  28. 28.
    Chou TC, Talalay P (1987) (eds) Applications of median-effect principle for the assessment of low-dose risk of carcinogenesis and for the quantification of synergism and antagonism of chemotherapeutic agents. In New Avenues in Development Cancer Chemotherapy, Bristol-Myers Series, New YorkGoogle Scholar
  29. 29.
    Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN (1990) Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res 50:1748–1756PubMedGoogle Scholar
  30. 30.
    Bosch S, Siavoshian S, Jacquot C, Tomasoni C, Dabouis G, Elanbaloussi Y et al (1997) Correlation between multidrug resistance and the degree of differentiation of non-small-cell bronchopulmonary carcinoma (NSCLC) in vitro and in vivo. Anticancer Res 17:4595–4598PubMedGoogle Scholar
  31. 31.
    Chadderton T, Wilson C, Bewick M, Gluck S (1997) Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR’s and measurement of low level gene expression in clinical samples. Cell Mol Biol 43:1227–1234PubMedGoogle Scholar
  32. 32.
    Wong H, Anderson WD, Cheng T, Riabowol KT (1994) Monitoring mRNA expression by polymerase chain reaction: the “primer-dropping” method. Anal Biochem 223:251–258PubMedCrossRefGoogle Scholar
  33. 33.
    NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O’Loughlin C, Daly C et al (1999) Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. Int J Cancer 82:368–376PubMedCrossRefGoogle Scholar
  34. 34.
    Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R (1991) Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49:630–637PubMedCrossRefGoogle Scholar
  35. 35.
    Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87:227–253PubMedCrossRefGoogle Scholar
  36. 36.
    Seminara P, Pastore C, Iascone C, Cicconetti F, Nigita G, Ielapi T, Franchi F (2007) Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem of schedule dependence in combination therapy. Chemotherapy 53:218–225PubMedCrossRefGoogle Scholar
  37. 37.
    O’Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300PubMedGoogle Scholar
  38. 38.
    Krynetskaia NF, Cai X, Nitiss JL, Krynetski EY, Relling MV (2000) Thioguanine substitution alters DNA cleavage mediated by topoisomerase II. FASEB J 14:2339–2344PubMedCrossRefGoogle Scholar
  39. 39.
    Ling YH, Chan JY, Beattie KL, Nelson JA (1992) Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol 42:802–807PubMedGoogle Scholar
  40. 40.
    Krynetskaia NF, Krynetski EY, Evans WE (1999) Human RNase H-mediated RNA cleavage from DNA–RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol 56:841–848PubMedGoogle Scholar
  41. 41.
    Wadler S, Green MD, Muggia FM (1986) Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell line. Cancer Res 46:1176–1181PubMedGoogle Scholar
  42. 42.
    Arrigo AP (1999) Gene expression and the thiol redox state. Free Radic Biol Med 27:936–944PubMedCrossRefGoogle Scholar
  43. 43.
    Sundseth R, MacDonald G, Ting J, King AC (1997) DNA elements recognizing NF-Y and Sp1 regulate the human multidrug-resistance gene promoter. Mol Pharmacol 51:963–971PubMedGoogle Scholar
  44. 44.
    Zhu Q, Center MS (1994) Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin. Cancer Res 54:4488–4492PubMedGoogle Scholar
  45. 45.
    Hochhauser D, Harris AL (1993) The role of topoisomerase II alpha and beta in drug resistance. Cancer Treat Rev 19:181–194PubMedCrossRefGoogle Scholar
  46. 46.
    Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL et al (2005) Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha. Mol Pharmacol 67:937–947PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Milica Pešić
    • 1
  • Tijana Andjelković
    • 1
  • Jasna Banković
    • 1
  • Ivanka D. Marković
    • 2
  • Ljubiša Rakić
    • 3
  • Sabera Ruždijić
    • 1
    • 4
    Email author
  1. 1.Institute for Biological Research, Department of NeurobiologyUniversity of BelgradeBelgradeRepublic of Serbia
  2. 2.Faculty of MedicineUniversity of BelgradeBelgradeRepublic of Serbia
  3. 3.Serbian Academy of Sciences and ArtsBelgradeRepublic of Serbia
  4. 4.Institute for Biological Research, Department of Neurobiology, Laboratory of Molecular NeurobiologyUniversity of BelgradeBelgradeRepublic of Serbia

Personalised recommendations